Loading...

EnBio Holdings

DB:0EJ
Snowflake Description

Moderate growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0EJ
DB
¥4B
Market Cap
  1. Home
  2. DE
  3. Commercial Services
Company description

EnBio Holdings, Inc focuses on soil and groundwater contamination, and renewable energy businesses in Japan. The last earnings update was 64 days ago. More info.


Add to Portfolio Compare Print
  • EnBio Holdings has significant price volatility in the past 3 months.
0EJ Share Price and Events
7 Day Returns
-4.3%
DB:0EJ
3.7%
DE Commercial Services
2.5%
DE Market
1 Year Returns
-66.4%
DB:0EJ
-8.4%
DE Commercial Services
-6.7%
DE Market
0EJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
EnBio Holdings (0EJ) -4.3% -10.8% -12.7% -66.4% -33.6% -
DE Commercial Services 3.7% 1.2% 12.5% -8.4% 3.6% -42.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 0EJ underperformed the Commercial Services industry which returned -8.4% over the past year.
  • 0EJ underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
0EJ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for EnBio Holdings's competitors could be found in our database.

0EJ Value

 Is EnBio Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for EnBio Holdings. This is due to cash flow or dividend data being unavailable. The share price is €4.452.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for EnBio Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are EnBio Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0EJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥12.28
TSE:6092 Share Price ** TSE (2019-04-18) in JPY ¥575
Europe Commercial Services Industry PE Ratio Median Figure of 105 Publicly-Listed Commercial Services Companies 16.91x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of EnBio Holdings.

DB:0EJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:6092 Share Price ÷ EPS (both in JPY)

= 575 ÷ 12.28

46.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • EnBio Holdings is overvalued based on earnings compared to the Europe Commercial Services industry average.
  • EnBio Holdings is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does EnBio Holdings's expected growth come at a high price?
Raw Data
DB:0EJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 46.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
25.9%per year
Europe Commercial Services Industry PEG Ratio Median Figure of 54 Publicly-Listed Commercial Services Companies 1.33x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for EnBio Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on EnBio Holdings's assets?
Raw Data
DB:0EJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥693.32
TSE:6092 Share Price * TSE (2019-04-18) in JPY ¥575
Germany Commercial Services Industry PB Ratio Median Figure of 8 Publicly-Listed Commercial Services Companies 2.04x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:0EJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:6092 Share Price ÷ Book Value per Share (both in JPY)

= 575 ÷ 693.32

0.83x

* Primary Listing of EnBio Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • EnBio Holdings is good value based on assets compared to the DE Commercial Services industry average.
X
Value checks
We assess EnBio Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. EnBio Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0EJ Future Performance

 How is EnBio Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover EnBio Holdings, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is EnBio Holdings expected to grow at an attractive rate?
  • EnBio Holdings's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • EnBio Holdings's earnings growth is expected to exceed the Germany market average.
  • Unable to compare EnBio Holdings's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0EJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0EJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 25.9%
Germany Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 31.4%
Germany Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 3.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0EJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0EJ Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:0EJ Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 9,095 79
2018-09-30 8,074 158 112
2018-06-30 8,396 239
2018-03-31 8,388 791 403
2017-12-31 8,521 396
2017-09-30 7,908 521 371
2017-06-30 6,803 261
2017-03-31 5,347 170 20
2016-12-31 3,374 9
2016-09-30 3,478 243 165
2016-06-30 2,684 157
2016-03-31 2,732 -418 142

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • EnBio Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if EnBio Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0EJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from EnBio Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0EJ Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:0EJ Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 12.28
2018-09-30 18.04
2018-06-30 40.06
2018-03-31 70.45
2017-12-31 72.15
2017-09-30 67.99
2017-06-30 47.87
2017-03-31 3.67
2016-12-31 1.66
2016-09-30 30.65
2016-06-30 31.01
2016-03-31 29.94

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if EnBio Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess EnBio Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
EnBio Holdings has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0EJ Past Performance

  How has EnBio Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare EnBio Holdings's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • EnBio Holdings has delivered over 20% year on year earnings growth in the past 5 years.
  • EnBio Holdings's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • EnBio Holdings's 1-year earnings growth is negative, it can't be compared to the Europe Commercial Services industry average.
Earnings and Revenue History
EnBio Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from EnBio Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0EJ Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 9,095.00 79.00 1,301.00
2018-09-30 8,074.00 112.00 1,224.00
2018-06-30 8,396.00 239.00 1,138.00
2018-03-31 8,388.00 403.00 1,103.00
2017-12-31 8,521.00 396.00 1,072.00
2017-09-30 7,908.00 371.00 1,058.00
2017-06-30 6,803.00 261.00 1,029.00
2017-03-31 5,347.00 20.00 940.00
2016-12-31 3,374.00 9.00 772.00
2016-09-30 3,478.00 165.00 675.00
2016-06-30 2,684.00 157.00 565.00
2016-03-31 2,732.00 142.00 547.00
2015-12-31 2,912.00 141.00 540.00
2015-09-30 2,472.00 65.00 510.00
2015-06-30 2,177.00 27.00 479.00
2015-03-31 1,979.00 12.00 459.00
2014-12-31 1,818.00 -33.00 440.00
2014-03-31 2,108.00 104.00 349.00
2013-03-31 1,493.00 61.00 331.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • EnBio Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • EnBio Holdings used its assets less efficiently than the Europe Commercial Services industry average last year based on Return on Assets.
  • EnBio Holdings's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess EnBio Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
EnBio Holdings has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0EJ Health

 How is EnBio Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up EnBio Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • EnBio Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • EnBio Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of EnBio Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from EnBio Holdings Company Filings, last reported 3 months ago.

DB:0EJ Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4,501.00 12,221.00 2,842.00
2018-09-30 4,610.00 11,889.00 2,806.00
2018-06-30 4,594.00 12,023.00 3,077.00
2018-03-31 4,506.00 12,164.00 3,515.00
2017-12-31 3,883.00 9,450.00 2,982.00
2017-09-30 2,832.00 9,268.00 1,370.00
2017-06-30 2,703.00 8,509.00 1,070.00
2017-03-31 2,602.00 7,631.00 1,600.00
2016-12-31 2,488.00 7,053.00 1,385.00
2016-09-30 2,677.00 6,329.00 2,501.00
2016-06-30 2,684.00 5,139.00 2,568.00
2016-03-31 2,553.00 3,844.00 1,952.00
2015-12-31 2,506.00 3,337.00 1,748.00
2015-09-30 1,444.00 3,478.00 968.00
2015-06-30 1,434.00 2,583.00 1,371.00
2015-03-31 1,437.00 1,990.00 1,064.00
2014-12-31 1,374.00 685.00 686.00
2014-03-31 1,383.00 485.00 1,074.00
2013-03-31 620.00 591.00 802.00
  • EnBio Holdings's level of debt (271.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (42.7% vs 271.5% today).
  • Debt is not well covered by operating cash flow (1.3%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.4x coverage).
X
Financial health checks
We assess EnBio Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. EnBio Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0EJ Dividends

 What is EnBio Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from EnBio Holdings dividends.
If you bought €2,000 of EnBio Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate EnBio Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate EnBio Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0EJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0EJ Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as EnBio Holdings has not reported any payouts.
  • Unable to verify if EnBio Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of EnBio Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as EnBio Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess EnBio Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can EnBio Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. EnBio Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0EJ Management

 What is the CEO of EnBio Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Minoru Nishimura
AGE 60
CEO Bio

Mr. Minoru Nishimura, Ph.D. serves as Co-President and Co-Chief Executive Officer of EnBioTec Laboratories Co., Ltd. Mr. Nishimura has been the President of Enbio Holdings, Inc. since January 2008 and serves as its Chief Executive Officer. He joined Lion Corp. in Apr 1981 and The Japan Research Institute, Ltd. in May 1990. He has been a Representative Director of Enbio Holdings, Inc. (formerly) since January 2008 and In Situ Solutions Co., Ltd. since January 2003. He has been a Director of In Situ Solution China Co., Ltd. since June 2012, K.K. Land Concierge since August 2006 and K.K. BF Management since March 2010. He served as a Director of EnBio Holdings, Inc. since June 2000.

CEO Compensation
  • Insufficient data for Minoru to compare compensation growth.
  • Insufficient data for Minoru to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Minoru Nishimura

TITLE
Chief Executive Officer
AGE
60
Board of Directors Tenure

Average tenure and age of the EnBio Holdings board of directors in years:

9
Average Tenure
50
Average Age
  • The tenure for the EnBio Holdings board of directors is about average.
Board of Directors

Minoru Nishimura

TITLE
Chief Executive Officer
AGE
60
TENURE
11.3 yrs

Yoshikazu Nakamura

TITLE
Director
AGE
45
TENURE
14.8 yrs

Hatsue Minato

TITLE
External Director
AGE
49
TENURE
4.8 yrs

Taichi Abe

TITLE
Director
AGE
46

Tadahide Kameyama

TITLE
External Director
AGE
44

Ichiro Namekawa

TITLE
External Standing Corporate Auditor
AGE
69
TENURE
6.8 yrs

Takahiro Hoshino

TITLE
External Auditor
AGE
63
TENURE
11.8 yrs

Koichiro Hirata

TITLE
External Auditor
AGE
51
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess EnBio Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. EnBio Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0EJ News

Simply Wall St News

0EJ Company Info

Description

EnBio Holdings, Inc focuses on soil and groundwater contamination, and renewable energy businesses in Japan. The company designs and executes environmental site assessment and site remediation works; and provides services relating to risks associated with subsurface contamination, such as clients support in their risk communication with local residents and public administrations, as well as environmental solutions. It also sells equipment and tools for soil and groundwater investigation and remediation; chemicals used for contaminated soil and groundwater remediation, as well as offers equipment and tools maintenance and technical support services in site application of the chemicals and equipment. In addition, the company purchases underused or idle lands; performs soil and/or groundwater treatment to reduce soil and groundwater contamination risks; and sells or rents regenerated land. EnBio Holdings, Inc was founded in 1999 and is headquartered in Tokyo, Japan.

Details
Name: EnBio Holdings, Inc
0EJ
Exchange: DB
Founded: 1999
¥29,703,681
6,499,132
Website: http://enbio-holdings.com
Address: EnBio Holdings, Inc
Kanda Park Plaza,
8th floor,
Tokyo,
101-0044,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 6092 Common Shares The Tokyo Stock Exchange JP JPY 12. Mar 2014
DB 0EJ Common Shares Deutsche Boerse AG DE EUR 12. Mar 2014
Number of employees
Current staff
Staff numbers
83
EnBio Holdings employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:07
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2018/05/15
Last earnings filing: 2019/02/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.